Bayer CropScience (506285) Q4 2002 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2002 earnings summary
19 Oct, 2026Executive summary
FY2002 sales fell amid severe drought, lower cotton and rice acreage, and weak pest pressure; Eastern-region growth and stronger herbicide and Environmental Science businesses partly offset the downturn.
Net profit after tax was Rs. 145.3 million; proposed dividend was Rs. 2 per share, or 20%.
Financial highlights
Gross sales were Rs. 3,328.2 million versus Rs. 4,664.4 million in 2001; net sales were Rs. 3,087.6 million versus Rs. 4,325.6 million.
Profit before extraordinary items and tax was Rs. 210.4 million versus Rs. 344.4 million; PAT was Rs. 145.3 million versus Rs. 309.2 million.
Extraordinary items included Rs. 7.3 million income from tenancy rights and Rs. 1.1 million voluntary retirement compensation; 2001 included Rs. 149.7 million income from marketing rights.
Export turnover rose to Rs. 182 million from Rs. 56 million, a reported 300% increase in the business performance review.
Outlook and guidance
FY2003 prospects were expected to be satisfactory, conditional on the monsoon; planned focus crops included rice, wheat, chillies, vegetables, and sugarcane.
Recovery in cotton, rice, horticulture, and soybean planted areas was anticipated for 2003, supporting improved business conditions.
Environmental Science expected to introduce several products in 2003; new launches were also expected to support future growth in vector control, termite management, and professional pest control.
Latest events from Bayer CropScience
- CropScience scale expanded through merger, while one-offs weighed on reported earnings.506285
Q4 2003 - PBT improved, but adjusted earnings faced portfolio, monsoon and pricing headwinds.506285
Q4 2004 - PAT rose 41% as market share advanced to 16% despite a 12% industry decline.506285
Q4 2005 - Profit rose as new products and seed distribution broadened growth plans; Thane closures triggered impairment.506285
Q4 2006 - 15-month PAT was Rs 491m; Thane restructuring costs offset investment-sale gains.506285
Q4 07/08 - PAT reached Rs. 944.59 million as new products met rising crop-protection demand.506285
Q4 08/09 - Sales and PAT rose as new launches supported growth amid pricing and operational risks.506285
Q4 09/10 - Revenue advanced and PAT grew modestly as innovation-led expansion met pricing and regulatory risks.506285
Q4 10/11 - Revenue and PAT rose despite a ₹579m Thane remediation charge.506285
Q4 11/12